戊酸雌二醇对去势大鼠子宫阴道雌激素受体α和β表达的影响研究
|
摘要
背景和目的
目前绝经期综合征多采用激素替代疗法(Hormone Replacement Therapy,HRT),但长期使用非对抗性雌激素易引发子宫内膜增生,增加子宫内膜腺癌的危险性。另外绝经期雌激素水平下降还可造成女性泌尿生殖道支撑组织萎缩和张力减退,引发压力性尿失禁(Stress urinary incontinence,SUI),而雌激素替代治疗SUI的疗效不甚理想,有学者假设可能与雌激素受体(Estrogen recepter,ER)亚型比例变化相关。子宫、阴道组织中ERα、ERβ分布及含量改变可以引起雌激素类药物作用效应的差异。目前关于绝经期子宫、阴道组织中ERα、ERβ的分布及含量变化,两种受体亚型介导雌激素生物效应的差异及相互作用,国内外的研究结果不相一致。
本研究采用免疫组化、免疫荧光双标(DLTI)激光扫描共聚焦显微镜(LSCM)及半定量RT-PCR技术,观察成年SD雌鼠、去势及药物干预后大鼠子宫、阴道ER亚型的分布及共表达状况,初步探讨ER亚型及ERα/ERβ值的变化与子宫内膜增殖、阴道萎缩之间的关系,为研究外源性雌激素对子宫、阴道ER亚型的调节及绝经后妇女合理补充雌激素提供理论和实验依据。
主要方法和结果
1. 80只4月龄体重320～350g健康雌性SD大鼠随机分为正常组、假手术组、去势组、去势+戊酸雌二醇组(药物组),每组20只。正常组未经干预,假手术组打开腹腔但不切除卵巢,药物组于术后4周用戊酸雌二醇生理盐水混悬液连续灌胃8周后处死大鼠。观察大鼠子宫、阴道大体形态学改变和组织学改变,并检测血中雌二醇和卵泡刺激素水平。结果:去势组于术后连续5天阴道上皮涂片染色无规律的动情期改变。去势组子宫、阴道明显萎缩,体积减小,药物组子宫、阴道湿重显著增加。HE染色去势组子宫内膜全层萎缩,腺体稀疏;阴道壁变薄,黏膜上皮萎缩。予雌激素后,子宫内膜明显增厚,腺体密集,偶可见腺腔囊状扩张;阴道壁轻度增厚,出现特征性皱褶结构。去势组大鼠血清雌二醇浓度明显降低、FSH水平明显升高,药物组E2水平较正常组、假手术组高。
2.免疫组化SP法检测ERα、ERβ蛋白;应用免疫荧光组织化学双标记染色技术,在激光共聚焦扫描显微镜下观察ERα、ERβ的表达情况;半定量RT-PCR检测ERα、ERβmRNA的表达水平。结果:1)去势组子宫ERα蛋白表达均较正常组和假手术组明显减弱,ERβ几乎未见表达,ERα/ERβ值升高。药物组ERα蛋白的表达较去势组、正常组和假手术组明显增强,ERβ表达无显著改变,ERα/ERβ值显著升高。去势组ER mRNA表达降低,以ERβ降低更显著。药物组ERαmRNA表达较去势组明显增强,甚至高于正常组。2)去势组阴道ERα蛋白表达水平较正常组、假手术组降低,ERβ表达水平下降更为明显,ERα/ERβ值升高。药物组鳞状上皮细胞ERα蛋白表达较去势组明显增强,基质纤维细胞和平滑肌细胞ERβ表达无改变,ERα/ERβ值显著升高。去势组ER mRNA表达均降低,以ERβ表达下降更为显著,药物组ERαmRNA表达较去势组明显增强。
结论:
1.从组织形态学和功能上均证实去势大鼠模型的成功建立。
2.去势大鼠子宫ERα、ERβmRNA及蛋白的表达均下降,以ERβmRNA和蛋白的表达下降更显著,ERα/ERβ值升高。戊酸雌二醇明显上调去势大鼠子宫ERαmRNA和蛋白的表达,对ERβmRNA和蛋白的表达无明显影响,ERα/ERβ值进一步升高。
3.去势引起的雌激素水平下降,造成阴道组织三种细胞ER亚型表达的下降或缺失,ERβmRNA和蛋白的表达下降更显著,ERα/ERβ值升高。雌激素替代治疗明显上调鳞状上皮细胞ERα蛋白的表达;ERT对基质纤维细胞和平滑肌细胞ERβ蛋白的表达无影响。
Background and objective
It is well-known that hormone replacement herapy(HRT) has become the principal therapic method in women with perimenopausal syndrome. However, long-term use of unopposed estrogens would induce endometrial hyperplasia and increase risk of adenocarcinoma endometrium. In addition, Decreased level of estrogen could lead to telatrophy and hypotonia of female genitourinary tract, and initiate stress urinary incontinence(SUI), but the therapeutic outcome with estrogen is not effective enough, so some researchers hypothesized that SUI might correlate with estrogen receptor. Changes of distribution and content of estrogen receptor alpha(ERα) and estrogen receptor beta(ERβ) could affect drug action of the estrogen. The research results were different about biological effect and interaction of the two subtypes.
In present study, we evaluated distribution and coexpression of ERα, ERβin uretus and vagina in adult male SD rats subjected to ovariedctomy and intervention of Estradiol Valerate after ovariedctomy, investigated relationship between changes of ER subtypes, ERα/ERβand endometrial hyperplasia and vaginal atrophy, provide theoretical basis for researching regulation of exogenous estrogen to ER subtypes of uretus and vagina, and appropriate supplying estrogen of postmenopause.
Main Methods and results
1. A total number of 80 female SD rats aged 4 months weighing about 340g each were randomly assigned into 4 groups: control group (n=20), sham-operated group (n=20), ovariectomied group (n=20) and drug group (n=20). The drug group was treated estradiol valerate everyday by intragastric administration after 4 weeks of Ovariectomy. The other three groups were medicated aequales normal saline by intragastric administration. 8 weeks later, all the rats were killed and the tissues of uterus and vagina and blood sample was collected. Morphological and histopathological changes of uretus and vagina were observed. Levels of estradiol and follicle stimulating hormone(FSH) in plasma were measured. The results showed that there were no estruation changes of vaginal epithelium detected in consecutive 5 days after ovariectomy. Uretus and vagina tissues became athophy, but they return to nomal after drug-taking. HE staining illustrated that endomembrance became atrophy and grand become rarefaction in ovariectomied group, and became thicker after drug-taking. Estradiol Level in plasma decreaed and plasma FSH content elevated significantly. Plasm Estradiol level rised and FSH concentration declined after taking estradiol valerate.
2. Immunohistochemistry method and Double-labelling technique of immunofluorescence(DLTI) +Laser scanning confocal microscopy(LSCM) was used to detect the expression and coexpression of ER-αand ER-βin superficial and deep compartments of the Uterus and vagina. The levels of mRNA gene expression of the two subtypes of estrogen receptors were measured by semi-quantitative RT-PCR. (1)The findings demonstrated that estrogen receptor alpha and beta were expressed in luminal epithelial cells, glandular epithelial cells, stromal fibroblast, vascular endothelial cells and the cell nucleus and cytoplasm of smooth muscle cells, especially in luminal epithelial cells and glandular epithelial cells. The Expression of ER alpha is significantly higher than that of ER beta. In terms of the expression of ER alpha, which in the ovariectomied group was lower than that of the control group and sham-operated group and the ratios of ER-α/ER-βis risen. However, there are nearly no expression of the ER beta in the ovariectomied group. The Expression of estrogen receptor alpha in the Uterus was significantly upregulated in drug group, whereas estrogen receptor beta was not upregulated significantly.(2)Estrogen receptor alpha and beta were expressed in squamous epithelial cells, stromal fibroblast, vascular endothelial cells, smooth muscle cells, especially in squamous epithelial cells. The Expression of ER alpha is significantly stronger than that of ER beta. Lower expression of ER isoforms, especially ER beta in ovariectomied group was showed.The Expression of estrogen receptor alpha in the vagina was significantly upregulated in drug group, whereas estrogen receptor beta was not significant up regulated.
Conclusions
1. successfully establishing animal model of Ovariectomy and drug intervention after Ovariectomy.
2. ER-αis a major subtype of Estrogen receptor expressed in uterus of rats. It was demonstrated that the expression of ER was shown lower after ovariectomy, especially that of ER-βand the ratios of ER-α/ER-βis risen. It suggested that estradiol valerate could upregulated expression of ER-αbut not contribution to ER-β.
3. ER-αis major expression isoforms of Estrogen receptor in vaginal tissue of rats. It was demonstrated down-regulation of ER-αand ER-βexpression in the vaginal tissues after ovariectomy, especially that of ER-βand the ratios of ER-α/ER-βis risen.The findings showed that estradiol valerate could upregulated expression of ER-αbut ER-β.
目前绝经期综合征多采用激素替代疗法(Hormone Replacement Therapy,HRT),但长期使用非对抗性雌激素易引发子宫内膜增生,增加子宫内膜腺癌的危险性。另外绝经期雌激素水平下降还可造成女性泌尿生殖道支撑组织萎缩和张力减退,引发压力性尿失禁(Stress urinary incontinence,SUI),而雌激素替代治疗SUI的疗效不甚理想,有学者假设可能与雌激素受体(Estrogen recepter,ER)亚型比例变化相关。子宫、阴道组织中ERα、ERβ分布及含量改变可以引起雌激素类药物作用效应的差异。目前关于绝经期子宫、阴道组织中ERα、ERβ的分布及含量变化,两种受体亚型介导雌激素生物效应的差异及相互作用,国内外的研究结果不相一致。
本研究采用免疫组化、免疫荧光双标(DLTI)激光扫描共聚焦显微镜(LSCM)及半定量RT-PCR技术,观察成年SD雌鼠、去势及药物干预后大鼠子宫、阴道ER亚型的分布及共表达状况,初步探讨ER亚型及ERα/ERβ值的变化与子宫内膜增殖、阴道萎缩之间的关系,为研究外源性雌激素对子宫、阴道ER亚型的调节及绝经后妇女合理补充雌激素提供理论和实验依据。
主要方法和结果
1. 80只4月龄体重320～350g健康雌性SD大鼠随机分为正常组、假手术组、去势组、去势+戊酸雌二醇组(药物组),每组20只。正常组未经干预,假手术组打开腹腔但不切除卵巢,药物组于术后4周用戊酸雌二醇生理盐水混悬液连续灌胃8周后处死大鼠。观察大鼠子宫、阴道大体形态学改变和组织学改变,并检测血中雌二醇和卵泡刺激素水平。结果:去势组于术后连续5天阴道上皮涂片染色无规律的动情期改变。去势组子宫、阴道明显萎缩,体积减小,药物组子宫、阴道湿重显著增加。HE染色去势组子宫内膜全层萎缩,腺体稀疏;阴道壁变薄,黏膜上皮萎缩。予雌激素后,子宫内膜明显增厚,腺体密集,偶可见腺腔囊状扩张;阴道壁轻度增厚,出现特征性皱褶结构。去势组大鼠血清雌二醇浓度明显降低、FSH水平明显升高,药物组E2水平较正常组、假手术组高。
2.免疫组化SP法检测ERα、ERβ蛋白;应用免疫荧光组织化学双标记染色技术,在激光共聚焦扫描显微镜下观察ERα、ERβ的表达情况;半定量RT-PCR检测ERα、ERβmRNA的表达水平。结果:1)去势组子宫ERα蛋白表达均较正常组和假手术组明显减弱,ERβ几乎未见表达,ERα/ERβ值升高。药物组ERα蛋白的表达较去势组、正常组和假手术组明显增强,ERβ表达无显著改变,ERα/ERβ值显著升高。去势组ER mRNA表达降低,以ERβ降低更显著。药物组ERαmRNA表达较去势组明显增强,甚至高于正常组。2)去势组阴道ERα蛋白表达水平较正常组、假手术组降低,ERβ表达水平下降更为明显,ERα/ERβ值升高。药物组鳞状上皮细胞ERα蛋白表达较去势组明显增强,基质纤维细胞和平滑肌细胞ERβ表达无改变,ERα/ERβ值显著升高。去势组ER mRNA表达均降低,以ERβ表达下降更为显著,药物组ERαmRNA表达较去势组明显增强。
结论:
1.从组织形态学和功能上均证实去势大鼠模型的成功建立。
2.去势大鼠子宫ERα、ERβmRNA及蛋白的表达均下降,以ERβmRNA和蛋白的表达下降更显著,ERα/ERβ值升高。戊酸雌二醇明显上调去势大鼠子宫ERαmRNA和蛋白的表达,对ERβmRNA和蛋白的表达无明显影响,ERα/ERβ值进一步升高。
3.去势引起的雌激素水平下降,造成阴道组织三种细胞ER亚型表达的下降或缺失,ERβmRNA和蛋白的表达下降更显著,ERα/ERβ值升高。雌激素替代治疗明显上调鳞状上皮细胞ERα蛋白的表达;ERT对基质纤维细胞和平滑肌细胞ERβ蛋白的表达无影响。
Background and objective
It is well-known that hormone replacement herapy(HRT) has become the principal therapic method in women with perimenopausal syndrome. However, long-term use of unopposed estrogens would induce endometrial hyperplasia and increase risk of adenocarcinoma endometrium. In addition, Decreased level of estrogen could lead to telatrophy and hypotonia of female genitourinary tract, and initiate stress urinary incontinence(SUI), but the therapeutic outcome with estrogen is not effective enough, so some researchers hypothesized that SUI might correlate with estrogen receptor. Changes of distribution and content of estrogen receptor alpha(ERα) and estrogen receptor beta(ERβ) could affect drug action of the estrogen. The research results were different about biological effect and interaction of the two subtypes.
In present study, we evaluated distribution and coexpression of ERα, ERβin uretus and vagina in adult male SD rats subjected to ovariedctomy and intervention of Estradiol Valerate after ovariedctomy, investigated relationship between changes of ER subtypes, ERα/ERβand endometrial hyperplasia and vaginal atrophy, provide theoretical basis for researching regulation of exogenous estrogen to ER subtypes of uretus and vagina, and appropriate supplying estrogen of postmenopause.
Main Methods and results
1. A total number of 80 female SD rats aged 4 months weighing about 340g each were randomly assigned into 4 groups: control group (n=20), sham-operated group (n=20), ovariectomied group (n=20) and drug group (n=20). The drug group was treated estradiol valerate everyday by intragastric administration after 4 weeks of Ovariectomy. The other three groups were medicated aequales normal saline by intragastric administration. 8 weeks later, all the rats were killed and the tissues of uterus and vagina and blood sample was collected. Morphological and histopathological changes of uretus and vagina were observed. Levels of estradiol and follicle stimulating hormone(FSH) in plasma were measured. The results showed that there were no estruation changes of vaginal epithelium detected in consecutive 5 days after ovariectomy. Uretus and vagina tissues became athophy, but they return to nomal after drug-taking. HE staining illustrated that endomembrance became atrophy and grand become rarefaction in ovariectomied group, and became thicker after drug-taking. Estradiol Level in plasma decreaed and plasma FSH content elevated significantly. Plasm Estradiol level rised and FSH concentration declined after taking estradiol valerate.
2. Immunohistochemistry method and Double-labelling technique of immunofluorescence(DLTI) +Laser scanning confocal microscopy(LSCM) was used to detect the expression and coexpression of ER-αand ER-βin superficial and deep compartments of the Uterus and vagina. The levels of mRNA gene expression of the two subtypes of estrogen receptors were measured by semi-quantitative RT-PCR. (1)The findings demonstrated that estrogen receptor alpha and beta were expressed in luminal epithelial cells, glandular epithelial cells, stromal fibroblast, vascular endothelial cells and the cell nucleus and cytoplasm of smooth muscle cells, especially in luminal epithelial cells and glandular epithelial cells. The Expression of ER alpha is significantly higher than that of ER beta. In terms of the expression of ER alpha, which in the ovariectomied group was lower than that of the control group and sham-operated group and the ratios of ER-α/ER-βis risen. However, there are nearly no expression of the ER beta in the ovariectomied group. The Expression of estrogen receptor alpha in the Uterus was significantly upregulated in drug group, whereas estrogen receptor beta was not upregulated significantly.(2)Estrogen receptor alpha and beta were expressed in squamous epithelial cells, stromal fibroblast, vascular endothelial cells, smooth muscle cells, especially in squamous epithelial cells. The Expression of ER alpha is significantly stronger than that of ER beta. Lower expression of ER isoforms, especially ER beta in ovariectomied group was showed.The Expression of estrogen receptor alpha in the vagina was significantly upregulated in drug group, whereas estrogen receptor beta was not significant up regulated.
Conclusions
1. successfully establishing animal model of Ovariectomy and drug intervention after Ovariectomy.
2. ER-αis a major subtype of Estrogen receptor expressed in uterus of rats. It was demonstrated that the expression of ER was shown lower after ovariectomy, especially that of ER-βand the ratios of ER-α/ER-βis risen. It suggested that estradiol valerate could upregulated expression of ER-αbut not contribution to ER-β.
3. ER-αis major expression isoforms of Estrogen receptor in vaginal tissue of rats. It was demonstrated down-regulation of ER-αand ER-βexpression in the vaginal tissues after ovariectomy, especially that of ER-βand the ratios of ER-α/ER-βis risen.The findings showed that estradiol valerate could upregulated expression of ER-αbut ER-β.
引文
1. Moalli PA, Talarico LC, Sung VW, et al.Impact of menopause on collagen subtypes in the arcus tendineous fasciae pelvis[J].Am J Obstet Gynecol 2004, 190(3): 620-627.
2. Swanson SG, Drosman S,Helmond FA,et al.Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind,placebo-controlled study. Menopause, 2006, 13(6):917-925.
3.苗明三.实验动物和动物实验技术.第三版.北京:中国中医药出版社,1997:165-166.
4.孙敬方.动物实验方法学.第一版.北京:人民卫生出版社,2001:423-426.
5. Danilovich N,Sairam MR,Maysinger D.The menopausal mouse:a new neural paradigm of a distressing human condition[J].Neu-roreport,2003,14(12):1617-1622.
6. Suzuki O, Koura M, Noguchi Y. Optimization of superovulation induction by human menopausal gonadotropin in guinea pigs based on follicular waves and FSH-receptor homologies[J].Mol Reprod Dev,2003,64(2):219-225.
7. Levine RL, Chen SJ,Durand J, et al.Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery[J]. Circulation, 1996, 94(9): 2221-2227.
8. Ylikorkala O, Cacciatore B, Paakkari I, et al. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane[J]. Fertil Steril, 1998, 69(5): 883-888.
9. Southeott BM. Careinoma of the endometrium. Drugs, 2001, 61(10):1395-1405.
10. Mylonas I, Jeschke U, Shabani N, et al. Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. Histol Histopathol, 2007, 22(2): 169-176.
11.蔡文琴.现代使用细胞与分子生物学实验技术[M].北京:人民军医出版社, 2003: 138-139, 111-137.
12. Pelletier G,Luu-TheV,Charbonneau A,et al.Cellular localization of estrogen receptor beta messenger ribonucleic aciol in cynomolgus monkey reproductive organs.Biol Reprod 1999,61(5):1249-1255。
13. Couse JF,Korach KS.Reproductive phenotypes in the estrogen receptor-alpha knockout mouse. Ann Endoerinol (Paris), 1999, 60(2):143-148.
14. Weihua Z,Saji S,Mokinen S,et al.Estrogen receptor(ER) beta, a modulator of ERalPha in the uterus .Proc Natl Aead Sei USA, 2000,97(11):5936-5941.
15. Taylor AH,AI-Azzawi F.Immunoloealization of estrogen receptor beta in bluman tissues.J Mol Endocrinal 2000, 24(l):145-155.
16. Jazaeri AA,Nunes KJ,Dalton MS,et al.Well-differentiated endometrial adeno carcinomas and poorly differentiated mixedmulle-rian tumors have altered ER and PR isoform expression[J].On-cogen, 2001, 20 (47): 6965-6969.
17. Saegusa M,Okayasu I..Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2status in normal and malignant endometrium[ J]. Jpn J Cancer Res, 2000, 91(5): 510-518.
18. Jazaeri AA,Nunes KJ,Dalton MS,et al.well-differentiated endometrial adeno carcinomas and Poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression oncogen 2001,20(47):6965-6969.
19. Hall JM,MeDonnell DP.The estrogen receptor beta-isoform(ERbeta) of the human estrogen receptor modulates ER alPha transcriptional aetivity and is a key regulator of the cellular response to estrogens and antiestrogens.Endocrinology, 1999, 140(12):5566-557.
20. Bardin A, BoulleN, LazennecG, et al. Loss ofER expression as a common step in estrogen-dependent tumor progression[J].EndocrRelatCancer, 2004, 11(3): 537-551.
21. Pettersson K,Delaunay F,Gustafsson JA,et al.Estrogen recptor beta act as adominant regulator of estrogen signals.oneogen, 2000, 19,(43):4970-4978.
22. Moalli PA, Talarico LC, Sung VW, et al. Impact of menopause on collagen subtypes in the arcus tendineous fasciae pelvis[J].Am J Obstet Gynecol 2004, 190(3): 620-627
23. Swanson SG, Drosman S,Helmond FA,et al.Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind,placebo-controlled study. Menopause, 2006, 13(6):917-925.
24. Swanson SG, Drosman S,Helmond FA,et al.Tibolone for the treatment of moderate tosevere vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind,placebo-controlled study. Menopause, 2006, 13(6):917-925.
25. Biri A, Durukan E, Maral I,et al Incidence of stress urinary incontinence among women in Turkey. Int Urogynecol J Pelvic Floor Dysfunct, 2006, 17(6):604-610.
26. Gebhart JB, Rickard DJ, Barrett TJ, et al. Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am J Obstet Gynecol, 2001, 185(6): 1325-1330.
27. Wada-Hiraike O, Hiraike H, Okinaga H, et al. Role of estrogen receptor beta in uterine stroma and epithelium: Insights from estrogen receptor beta-/- mice. Proc Natl Acad Sci USA,2006, 28, 103(48): 18350-18355.
28. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a no-vel receptor expressed in rat prostate and ovary[ J]. Proc Natl Acad Sci USA, 1996, 93(12): 5925-5930.
1. Greene GL, Gilna P, Waterfield M, et al. Sequence and expression of human estrogen receptor complementary DNA[J].Science, 1986, 231(4742): 1150-1154.
2. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel estrogen receptors expressed in rat prostate and ovary[J]. Proc Nat Acad Sci USA, 1996, 93(12): 5925-5930.
3. Mosselman S, Polman J, Dijkema R. ERβ: identification andcharacterization of a novel estrogen receptor[J]. FEBS Lett,1996(1), 392: 49-53.
4. Greschik H, Flaig J, Renaud P, et al. Structural basis for the deactivation of the estrogen-related receptor by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity[J]. J Biol Chem, 2004; 279(32): 33639-33646.
5. Luo J, Sladek R, Carrier J, et al. Reduced fat mass in mice lacking orphan nuclear receptor estrogen-related receptors[J]. Mol Cell Biol, 2003, 23(22): 7947-7956.
6. Shaaban AM, JarvisC, Moore F, et al. Prognostic significance of estrogen receptor beta in epithelial hyperplasia of usual type with known outcome[J]. Am J Surg Pathol, 2005, 29(12): 1593-1599.
7 Gustafsson J. Estrogen receptorβ-αnew dimension in estrogen mechanism of action[J]. J Endocrinol,1999, 163(3): 379-383.
8. Muramastu M, Inove S. Estrogen receptors: How do they control reproductive and norreproductive function[J]? Biophys Res Commun, 2000, 270(1): 1-10.
9. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease[J]. Endocr Rev, 2004, 25(6): 869-898.
10. Ogawa S, Inoue S, Watanabe T, et al·The complete primary structure of human estrogen receptor beta(hER beta) and its heterodimerization with ER alpha in vivo and in vitro[J]. Biochem Biophys Res Commun, 1998, 243(1): 122-126.
11. Mowa CN, Iwanaga T. Differential distribution of oestrogen receptor-alpha and -beta mRNAs in the female reproductive organ of rats as revealed by in situ hybridization[J]. J Endocrinol ,2000,165(1): 59-66.
12. Ann E, Drummond G, Anna J, et al. Ovarian estrogen receptorαandβmRNAexpression: impact of development and estrogen[J]. Molecular Cellular Endocrinol, 1999; 149(2): 153-161.
13. Medeiros R, Vasconcelos A, Costa S, et al. Steroid hormone genotypes ARStuI and ER325 are linked to the progression of human prostate cancer[J]. Cancer Genet Cytogenet, 2003; 141(2): 91-96.
14. Sims NA, Dupont S, Krust A, et al. Deletion of estrogen receptors reveals a regulatory role f or estrogen receptors2beta in bone remodeling in females but not in males[J]. Bone, 2002, 30(1): 18-25.
15. Lindberg MK, Alatalo SL, Halleen JM, et al. Estrogen receptor specificity in the regulation of the skeleton in female mice[J]. J Endocrinol, 2001, 171(2): 229-236.
16. Gennari L, Merlotti D, Paola V. Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a huge review[J]. Am J Epidemio, 2005, 161(4): 307-320.
17. Schoenau E. Bone mass increase in puberty: what makes it happen[J]. Horm Res, 2006, 65(S2): S2-S10.
18. Perez SE, Chen EY, Mufson EJ. Distribution of estrogen receptor alpha and beta immunoreactive profiles in the postnatal rat brain[J]. Brain Res Dev Brain Res, 2003, 145(12): 117-139.
19. Shughrue PJ, Merchenthaler I. Evidence for novel estrogen binding sites in the rathippocampus[J]. Neuroscience, 2000, 99(4): 605-612.
20. Kalita K, Szymczak S, Kaczmarek L. Non-nuclear estrogen receptorαandβin the hippocampus ofmale and female rats[J]. Hippocampus, 2005, 15(1): 404-412.
21. RuneGM, Wehrenberg U, Prange KJ. Estrogen up-regulates estrogen receptor k and synaptophysin in slice cultures of rat[J].Hippocampus Neurosci, 2002, 113(1): 167-175.
22. Bruce SM. The molecular and neuroanat omical basis f or estrogen effects in t he cent ral neuvous system[J]. J CE&M, 1999, 84(6): 1790-1797.
23 Alvaco D, Mancino MG, Onori P, etal·Estrogens and the pathophysiology of the billary tree[J]. World JGastroenterol, 2006, 12(5): 3537-3545.
24. Hodges YK , Tung L , Yan XD , et al . Estrogen receptors alpha and beta, prevalence of estrogen recept or beta mRNA in human vascular smooth muscle and transcriptional effects[J]. Circulation, 2000, 101(15):1792-1798.
25. SakaguchiH, Fujimoto J, Bao LH,et al. Quantitative analysis of estrogen recept-proteins in rat ovary[J]. J Steroid Biochem Mole Bio, 2005, 94(7): 83-91.
26. Fixemer T, Remberger K, Bonkhof H. Differential expression of the estrogen receptorbeta(ERbeta) in human prostate trssue, premalignantchanges, and in primary, metastatic, and recurrentprostatic adenocarcinoma[J]. Prostate, 2003, 54(2): 79-87.
27. Somponpun SJ, Sladek CD·Osmotic regulation of estrogen receptor-beta in rat vasopressin and oxytocin neurons[J]. J Neurosci, 2003, 23(1): 4261-4269.
28. Zofkova I, Zajickova K , Hill M. The est rogen recept or alpha gene determines serum androstenedione levels in p ostmenopausal women[J]. Steroids, 2002, 67(10): 815-819.
29. Gebhart JB, Rickard DJ, Barrett TJ, et al. Expression of estrogen recept or isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women[J]. Am J Obstet Gynecol, 2001, 185(6): 1325-1330.
30. Jazaeri AA, Nunes KJ, Dalton MS, et al. Well differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression[J]. Oncogene, 2001, 20(47): 6965-6969.
31. Kruijver FP, Swaab DF. Sex hormone receptors are p resent in the human sup rachiasmatic nucleus[J]. Neuroendocrinology, 2002, 75(5):296-305.
32. Jakimiuk AJ, Bogusiewicz M, Skorupski P, et al. Relationship between estrogen receptor-alpha polymorphism and serum levels of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, C-reactive protein and homocysteine in postmenopausal women. Gynecol Endocrinol, 2007, 23(10): 584-589.
33. Folwarczna J, Sliwinski L, Cegiela U, et al.Raloxifene similarly affects the skeletal system of male and ovariectomized female rats[J]. Pharmacol Rep, 2007; 59(3): 349-358.
34. Tiwari-Woodruff S, Morales L-B, Lee R, et al. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment[J]. Proc Natl Acad Sci USA, 2007, 104(37): 14813-14818.
35. Shimizu I , Inoue H , Yano M , et al . Estrogen receptor levels and lipid peroxidation in hepatocellular carcinoma with hepatitis C virus inf ection[J]. Liver ,2001 ,21 (5) :342-349.
1. Li AJ, Baldwin RL, Karlan BY. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstert Gynecol, 2003, 189(1):22-27.
2. NRN Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell, 1999, 97: 161–163.
3. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erbA. Nature, 1986: 320: 134-139.
4. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. Fed Eur Biochem Soc Lett, 1996, 392: 49–53.
5. Kelley ST, Thackray VG. Phylogenetic analyses reveal ancient duplication of estrogen receptor isoforms. J Mol Evol, 1999, 49: 609–614.
6. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor betagene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab, 1997, 82: 4258–4265.
7. Poola I, Abraham J, Baldwin K. Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor beta mRNA is distinct from that of estrogen receptor alpha. FEBS Lett, 2002, 516(1-3): 133-138.
8. Brandenberger AW, Tee MK, Jaffe RB. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab, 1998, 83: 1025–1028.
9. O'Donnell AJ, Macleod KG, Burns DJ, et al. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen[J]. Endocr Relat Cancer.2005, 12(4): 851-866.
10. MylonasI, Jeschke U, Shabani N, et al. Immunohistochemical analysis of estrogenreceptor alpha, estrogen receptor beta and progesterone receptor in normal human endometrium. Acta Histochem, 2004, 106(3): 245-252.
11. Fu X, Rezapour M, Wu X, et al. Expression of estrogen receptor-alpha and -beta in anterior vaginal walls of genuine stress incontinent women. Int Urogynecol J Pelvic Floor Dysfunct, 2003, 14(4): 276-281.
12. Knaapen MW, Somers P, Bortier H, et al. Smooth muscle cell hypertrophy in varicose veins is associated with expression of estrogen receptor-beta. J Vasc Res, 2005, 42(1): 8-12.
13. Sumi K, Matsuyama S, Kitajima Y, et al. Loss of estrogen receptor beta expression at cancer front correlates with tumor progression and poor prognosis of gallbladder cancer. OncolRep, 2004, 12(5): 979-984.
14. Maliqueo M, Clementi M, Gabler F, et al. Expression of steroid receptors and proteins related to apoptosis in endometria of women with polycystic ovary syndrome. Fertil Steril, 2003, 80 (suppl. 2): 812–819.
15. Matsuzaki S, Fukaya T, Uehara S, et al. Characterization of messenger RNA expression of estrogen receptor-alpha and -beta in patients with ovarian endometriosis. Fertil Steril, 2000, 73: 1219–1225.
16. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA, 1999, 96: 5722–5727.
17. Lindgren PR, Cajander S, Backstrom T, et al. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol, 2004, 221(1-2): 97-104.
18. Hayashi SI, Eguchi H, Tanimoto K, et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer, 2003, 10(2): 193-202.
19. Rodriguez C, Calle EE, Coates RJ, et al. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol, 2005, 141: 828–835.
20. Mant JW, Vessey MP. Ovarian and endometrial cancers. Cancer Surv, 1994, 19: 287–307.
21. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet, 1971, 2: 163.Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst, 1998 90: 1774–1786.
22. Auranen A, Hietanen S, Salami T, et al. Hormonal treatments and epithelial ovarian cancer risk. Int J Gynecol Cancer, 2005,15 (5):692-700.
23. Gambacciani M, Monteleone P, Sacco A, et al. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab, 2003, 17: 139–147.
24. Brekelmans CT. Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol, 2003, 15: 63–68.
25. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). J Am Med Assoc, 2002, 288: 58-66.
26. Murdoch WJ, McDonnel AC. Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction, 2002, 123: 743–750.
27. Lacey Jr JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. J Am Med Assoc, 2002, 288: 334–341.
28. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. J Am Med Assoc, 2003, 290: 1739–1748.
29. Schomberg DW, Couse JF, Mukherjee A, et al. Targeted disruption of the estrogen receptor-alpha gene in female mice: characterization of ovarian responses and phenotype in the adult. Endocrinology, 1999, 140: 2733–2744.
30. Cheng G, Weihua Z, Makinen S, et al. A role for the androgen receptor in follicular atresia of estrogen receptor beta knockout mouse ovary. Biol Reprod, 2002, 66: 77–84.
31. Cheng J, Lee EJ, Madison LD, et al. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett, 2004, 566(1-3): 169-172.
32. Temple JL, Scordalakes EM, Bodo C, et al.Lack of functional estrogen receptor beta gene disrupts pubertal male sexual behavior. Horm Behav, 2003, 44(5): 427-434.
33. Delbes G, Levacher C, Pairault C, et al. Estrogen receptor beta-mediated inhibition of male germ cell line development in mice by endogenous estrogens during perinatal life. Endocrinology, 2004, 145(7): 3395-3403.
34. Couse JF, Hewitt SC, Bunch DO, et al. postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta. Science, 1999, 286(5448): 2328-2331.
35. Couse JF, Yates MM, Walker VR, et al. Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) Null mice reveals hypergonadism and endocrine sex reversal in females lacking ERalpha but not ERbeta. Mol Endocrinol, 2003, 17(6): 1039-1053.
36. Horvath LG, Henshall SM, Lee CS, et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res, 2001, 61: 5331–5335.
37. Roger P, Sahla ME, Makela S, et al. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res, 2001, 61: 2537–2541.
38. Hartinan J,Lindberg K,Morani A,InZunZa J,Strom A,Gustafsson JA. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res,2006,66:11207-11213
39. Stabile LP, Davis ALG, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor a and b and show biological responses to estrogen. Cancer Res, 2002, 62: 2141–2150.
40. Foley EF, Jazaeri AA, Shupnik MA, et al. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res, 2000, 60: 245–248.
41.李建文,陶凯雄,蔡开琳. ERβ和VEGF在大肠癌中的表达及临床意义.世界华人消化杂志2007,15(24):2652-2656
42. Chu S, Mamers P, Burger HG, et al. Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors. J Clin Endocrinol Metab, 2000, 85: 1200–1205.
43. Rutherford T, Brown WD, Sapi E,et al. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol, 2000, 96: 417–421.
44. Bardin A, Hoffmann P, Boulle N, et al. Involvement of estrogen receptor beta inovarian carcinogenesis. Cancer Res, 2004, 64(16): 5861-5869.
45. Li AJ, Baldwin RL, Karlan BY. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am JObstet Gynecol, 2003, 189: 22–27.
46. Lindgren PR, Cajander S, Backstrom T, et al. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol, 2004, 221:97–104.
47. Skliris GP, Munot K, Bell SM, et al. Reduced expression of oestrogen receptor-beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol, 2003, 201: 213–220.
48. Sasaki M, Tanaka Y, Perinchery G, et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst, 2002, 94: 384–390.
49.姚青,何晓松,张建民.前列腺癌中E-钙粘素、p16及雌激素受体基因甲基化的检测及其临床意义[J].中华男科学, 2007, 12(1): 28-31.
50. Li LC, Yeh CC, Nojima D, et al. Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun, 2000, 275: 682–689.
51. Bandera CA, Takahashi H, Behbakht K,et al.Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma. Cancer Res, 1997, 57: 513–515.
52. Cheng J, Lee EJ, Madison LD, et al. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. Fed Eur Biochem Soc Lett, 2004, 566: 169–172.
53. Licznar A, Caporali S, Lucas A, et al. Identification of genes involved in growth inhibition of breast cancer cells transduced with estrogen receptor.Fed Eu. Biochem Soc Lett, 2003, 553: 445–450.
54. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, et al. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene, 2003, 22: 5011–5020.
55. Paruthiyil S, Parmar H, Kerekatte V, et al. Estrogen receptor beta inhibits human breastcancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res, 2004, 64: 423–428.
56. Strom A, Hartman J, Foster JS, et al. Estrogen receptor b inhibits 17b- estradiolstimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA, 2004.
57. Sapi E, Brown WD, Aschkenazi S, et al. Regulation of Fas ligand expression by estrogen in normal ovary. J Soc Gynecol Investig, 2002, 9: 243–250.
58. Meng-Sen L,i Qiu-LingMa, Qian Chen, et al Alpha-fetoprotein triggers hematoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells[J].World Journal of Gastroen tectology, 2005, 11(17): 2564-2569.
2. Swanson SG, Drosman S,Helmond FA,et al.Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind,placebo-controlled study. Menopause, 2006, 13(6):917-925.
3.苗明三.实验动物和动物实验技术.第三版.北京:中国中医药出版社,1997:165-166.
4.孙敬方.动物实验方法学.第一版.北京:人民卫生出版社,2001:423-426.
5. Danilovich N,Sairam MR,Maysinger D.The menopausal mouse:a new neural paradigm of a distressing human condition[J].Neu-roreport,2003,14(12):1617-1622.
6. Suzuki O, Koura M, Noguchi Y. Optimization of superovulation induction by human menopausal gonadotropin in guinea pigs based on follicular waves and FSH-receptor homologies[J].Mol Reprod Dev,2003,64(2):219-225.
7. Levine RL, Chen SJ,Durand J, et al.Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery[J]. Circulation, 1996, 94(9): 2221-2227.
8. Ylikorkala O, Cacciatore B, Paakkari I, et al. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane[J]. Fertil Steril, 1998, 69(5): 883-888.
9. Southeott BM. Careinoma of the endometrium. Drugs, 2001, 61(10):1395-1405.
10. Mylonas I, Jeschke U, Shabani N, et al. Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. Histol Histopathol, 2007, 22(2): 169-176.
11.蔡文琴.现代使用细胞与分子生物学实验技术[M].北京:人民军医出版社, 2003: 138-139, 111-137.
12. Pelletier G,Luu-TheV,Charbonneau A,et al.Cellular localization of estrogen receptor beta messenger ribonucleic aciol in cynomolgus monkey reproductive organs.Biol Reprod 1999,61(5):1249-1255。
13. Couse JF,Korach KS.Reproductive phenotypes in the estrogen receptor-alpha knockout mouse. Ann Endoerinol (Paris), 1999, 60(2):143-148.
14. Weihua Z,Saji S,Mokinen S,et al.Estrogen receptor(ER) beta, a modulator of ERalPha in the uterus .Proc Natl Aead Sei USA, 2000,97(11):5936-5941.
15. Taylor AH,AI-Azzawi F.Immunoloealization of estrogen receptor beta in bluman tissues.J Mol Endocrinal 2000, 24(l):145-155.
16. Jazaeri AA,Nunes KJ,Dalton MS,et al.Well-differentiated endometrial adeno carcinomas and poorly differentiated mixedmulle-rian tumors have altered ER and PR isoform expression[J].On-cogen, 2001, 20 (47): 6965-6969.
17. Saegusa M,Okayasu I..Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2status in normal and malignant endometrium[ J]. Jpn J Cancer Res, 2000, 91(5): 510-518.
18. Jazaeri AA,Nunes KJ,Dalton MS,et al.well-differentiated endometrial adeno carcinomas and Poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression oncogen 2001,20(47):6965-6969.
19. Hall JM,MeDonnell DP.The estrogen receptor beta-isoform(ERbeta) of the human estrogen receptor modulates ER alPha transcriptional aetivity and is a key regulator of the cellular response to estrogens and antiestrogens.Endocrinology, 1999, 140(12):5566-557.
20. Bardin A, BoulleN, LazennecG, et al. Loss ofER expression as a common step in estrogen-dependent tumor progression[J].EndocrRelatCancer, 2004, 11(3): 537-551.
21. Pettersson K,Delaunay F,Gustafsson JA,et al.Estrogen recptor beta act as adominant regulator of estrogen signals.oneogen, 2000, 19,(43):4970-4978.
22. Moalli PA, Talarico LC, Sung VW, et al. Impact of menopause on collagen subtypes in the arcus tendineous fasciae pelvis[J].Am J Obstet Gynecol 2004, 190(3): 620-627
23. Swanson SG, Drosman S,Helmond FA,et al.Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind,placebo-controlled study. Menopause, 2006, 13(6):917-925.
24. Swanson SG, Drosman S,Helmond FA,et al.Tibolone for the treatment of moderate tosevere vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind,placebo-controlled study. Menopause, 2006, 13(6):917-925.
25. Biri A, Durukan E, Maral I,et al Incidence of stress urinary incontinence among women in Turkey. Int Urogynecol J Pelvic Floor Dysfunct, 2006, 17(6):604-610.
26. Gebhart JB, Rickard DJ, Barrett TJ, et al. Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am J Obstet Gynecol, 2001, 185(6): 1325-1330.
27. Wada-Hiraike O, Hiraike H, Okinaga H, et al. Role of estrogen receptor beta in uterine stroma and epithelium: Insights from estrogen receptor beta-/- mice. Proc Natl Acad Sci USA,2006, 28, 103(48): 18350-18355.
28. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a no-vel receptor expressed in rat prostate and ovary[ J]. Proc Natl Acad Sci USA, 1996, 93(12): 5925-5930.
1. Greene GL, Gilna P, Waterfield M, et al. Sequence and expression of human estrogen receptor complementary DNA[J].Science, 1986, 231(4742): 1150-1154.
2. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel estrogen receptors expressed in rat prostate and ovary[J]. Proc Nat Acad Sci USA, 1996, 93(12): 5925-5930.
3. Mosselman S, Polman J, Dijkema R. ERβ: identification andcharacterization of a novel estrogen receptor[J]. FEBS Lett,1996(1), 392: 49-53.
4. Greschik H, Flaig J, Renaud P, et al. Structural basis for the deactivation of the estrogen-related receptor by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity[J]. J Biol Chem, 2004; 279(32): 33639-33646.
5. Luo J, Sladek R, Carrier J, et al. Reduced fat mass in mice lacking orphan nuclear receptor estrogen-related receptors[J]. Mol Cell Biol, 2003, 23(22): 7947-7956.
6. Shaaban AM, JarvisC, Moore F, et al. Prognostic significance of estrogen receptor beta in epithelial hyperplasia of usual type with known outcome[J]. Am J Surg Pathol, 2005, 29(12): 1593-1599.
7 Gustafsson J. Estrogen receptorβ-αnew dimension in estrogen mechanism of action[J]. J Endocrinol,1999, 163(3): 379-383.
8. Muramastu M, Inove S. Estrogen receptors: How do they control reproductive and norreproductive function[J]? Biophys Res Commun, 2000, 270(1): 1-10.
9. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease[J]. Endocr Rev, 2004, 25(6): 869-898.
10. Ogawa S, Inoue S, Watanabe T, et al·The complete primary structure of human estrogen receptor beta(hER beta) and its heterodimerization with ER alpha in vivo and in vitro[J]. Biochem Biophys Res Commun, 1998, 243(1): 122-126.
11. Mowa CN, Iwanaga T. Differential distribution of oestrogen receptor-alpha and -beta mRNAs in the female reproductive organ of rats as revealed by in situ hybridization[J]. J Endocrinol ,2000,165(1): 59-66.
12. Ann E, Drummond G, Anna J, et al. Ovarian estrogen receptorαandβmRNAexpression: impact of development and estrogen[J]. Molecular Cellular Endocrinol, 1999; 149(2): 153-161.
13. Medeiros R, Vasconcelos A, Costa S, et al. Steroid hormone genotypes ARStuI and ER325 are linked to the progression of human prostate cancer[J]. Cancer Genet Cytogenet, 2003; 141(2): 91-96.
14. Sims NA, Dupont S, Krust A, et al. Deletion of estrogen receptors reveals a regulatory role f or estrogen receptors2beta in bone remodeling in females but not in males[J]. Bone, 2002, 30(1): 18-25.
15. Lindberg MK, Alatalo SL, Halleen JM, et al. Estrogen receptor specificity in the regulation of the skeleton in female mice[J]. J Endocrinol, 2001, 171(2): 229-236.
16. Gennari L, Merlotti D, Paola V. Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a huge review[J]. Am J Epidemio, 2005, 161(4): 307-320.
17. Schoenau E. Bone mass increase in puberty: what makes it happen[J]. Horm Res, 2006, 65(S2): S2-S10.
18. Perez SE, Chen EY, Mufson EJ. Distribution of estrogen receptor alpha and beta immunoreactive profiles in the postnatal rat brain[J]. Brain Res Dev Brain Res, 2003, 145(12): 117-139.
19. Shughrue PJ, Merchenthaler I. Evidence for novel estrogen binding sites in the rathippocampus[J]. Neuroscience, 2000, 99(4): 605-612.
20. Kalita K, Szymczak S, Kaczmarek L. Non-nuclear estrogen receptorαandβin the hippocampus ofmale and female rats[J]. Hippocampus, 2005, 15(1): 404-412.
21. RuneGM, Wehrenberg U, Prange KJ. Estrogen up-regulates estrogen receptor k and synaptophysin in slice cultures of rat[J].Hippocampus Neurosci, 2002, 113(1): 167-175.
22. Bruce SM. The molecular and neuroanat omical basis f or estrogen effects in t he cent ral neuvous system[J]. J CE&M, 1999, 84(6): 1790-1797.
23 Alvaco D, Mancino MG, Onori P, etal·Estrogens and the pathophysiology of the billary tree[J]. World JGastroenterol, 2006, 12(5): 3537-3545.
24. Hodges YK , Tung L , Yan XD , et al . Estrogen receptors alpha and beta, prevalence of estrogen recept or beta mRNA in human vascular smooth muscle and transcriptional effects[J]. Circulation, 2000, 101(15):1792-1798.
25. SakaguchiH, Fujimoto J, Bao LH,et al. Quantitative analysis of estrogen recept-proteins in rat ovary[J]. J Steroid Biochem Mole Bio, 2005, 94(7): 83-91.
26. Fixemer T, Remberger K, Bonkhof H. Differential expression of the estrogen receptorbeta(ERbeta) in human prostate trssue, premalignantchanges, and in primary, metastatic, and recurrentprostatic adenocarcinoma[J]. Prostate, 2003, 54(2): 79-87.
27. Somponpun SJ, Sladek CD·Osmotic regulation of estrogen receptor-beta in rat vasopressin and oxytocin neurons[J]. J Neurosci, 2003, 23(1): 4261-4269.
28. Zofkova I, Zajickova K , Hill M. The est rogen recept or alpha gene determines serum androstenedione levels in p ostmenopausal women[J]. Steroids, 2002, 67(10): 815-819.
29. Gebhart JB, Rickard DJ, Barrett TJ, et al. Expression of estrogen recept or isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women[J]. Am J Obstet Gynecol, 2001, 185(6): 1325-1330.
30. Jazaeri AA, Nunes KJ, Dalton MS, et al. Well differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression[J]. Oncogene, 2001, 20(47): 6965-6969.
31. Kruijver FP, Swaab DF. Sex hormone receptors are p resent in the human sup rachiasmatic nucleus[J]. Neuroendocrinology, 2002, 75(5):296-305.
32. Jakimiuk AJ, Bogusiewicz M, Skorupski P, et al. Relationship between estrogen receptor-alpha polymorphism and serum levels of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, C-reactive protein and homocysteine in postmenopausal women. Gynecol Endocrinol, 2007, 23(10): 584-589.
33. Folwarczna J, Sliwinski L, Cegiela U, et al.Raloxifene similarly affects the skeletal system of male and ovariectomized female rats[J]. Pharmacol Rep, 2007; 59(3): 349-358.
34. Tiwari-Woodruff S, Morales L-B, Lee R, et al. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment[J]. Proc Natl Acad Sci USA, 2007, 104(37): 14813-14818.
35. Shimizu I , Inoue H , Yano M , et al . Estrogen receptor levels and lipid peroxidation in hepatocellular carcinoma with hepatitis C virus inf ection[J]. Liver ,2001 ,21 (5) :342-349.
1. Li AJ, Baldwin RL, Karlan BY. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstert Gynecol, 2003, 189(1):22-27.
2. NRN Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell, 1999, 97: 161–163.
3. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erbA. Nature, 1986: 320: 134-139.
4. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. Fed Eur Biochem Soc Lett, 1996, 392: 49–53.
5. Kelley ST, Thackray VG. Phylogenetic analyses reveal ancient duplication of estrogen receptor isoforms. J Mol Evol, 1999, 49: 609–614.
6. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor betagene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab, 1997, 82: 4258–4265.
7. Poola I, Abraham J, Baldwin K. Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor beta mRNA is distinct from that of estrogen receptor alpha. FEBS Lett, 2002, 516(1-3): 133-138.
8. Brandenberger AW, Tee MK, Jaffe RB. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab, 1998, 83: 1025–1028.
9. O'Donnell AJ, Macleod KG, Burns DJ, et al. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen[J]. Endocr Relat Cancer.2005, 12(4): 851-866.
10. MylonasI, Jeschke U, Shabani N, et al. Immunohistochemical analysis of estrogenreceptor alpha, estrogen receptor beta and progesterone receptor in normal human endometrium. Acta Histochem, 2004, 106(3): 245-252.
11. Fu X, Rezapour M, Wu X, et al. Expression of estrogen receptor-alpha and -beta in anterior vaginal walls of genuine stress incontinent women. Int Urogynecol J Pelvic Floor Dysfunct, 2003, 14(4): 276-281.
12. Knaapen MW, Somers P, Bortier H, et al. Smooth muscle cell hypertrophy in varicose veins is associated with expression of estrogen receptor-beta. J Vasc Res, 2005, 42(1): 8-12.
13. Sumi K, Matsuyama S, Kitajima Y, et al. Loss of estrogen receptor beta expression at cancer front correlates with tumor progression and poor prognosis of gallbladder cancer. OncolRep, 2004, 12(5): 979-984.
14. Maliqueo M, Clementi M, Gabler F, et al. Expression of steroid receptors and proteins related to apoptosis in endometria of women with polycystic ovary syndrome. Fertil Steril, 2003, 80 (suppl. 2): 812–819.
15. Matsuzaki S, Fukaya T, Uehara S, et al. Characterization of messenger RNA expression of estrogen receptor-alpha and -beta in patients with ovarian endometriosis. Fertil Steril, 2000, 73: 1219–1225.
16. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA, 1999, 96: 5722–5727.
17. Lindgren PR, Cajander S, Backstrom T, et al. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol, 2004, 221(1-2): 97-104.
18. Hayashi SI, Eguchi H, Tanimoto K, et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer, 2003, 10(2): 193-202.
19. Rodriguez C, Calle EE, Coates RJ, et al. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol, 2005, 141: 828–835.
20. Mant JW, Vessey MP. Ovarian and endometrial cancers. Cancer Surv, 1994, 19: 287–307.
21. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet, 1971, 2: 163.Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst, 1998 90: 1774–1786.
22. Auranen A, Hietanen S, Salami T, et al. Hormonal treatments and epithelial ovarian cancer risk. Int J Gynecol Cancer, 2005,15 (5):692-700.
23. Gambacciani M, Monteleone P, Sacco A, et al. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab, 2003, 17: 139–147.
24. Brekelmans CT. Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol, 2003, 15: 63–68.
25. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). J Am Med Assoc, 2002, 288: 58-66.
26. Murdoch WJ, McDonnel AC. Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction, 2002, 123: 743–750.
27. Lacey Jr JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. J Am Med Assoc, 2002, 288: 334–341.
28. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. J Am Med Assoc, 2003, 290: 1739–1748.
29. Schomberg DW, Couse JF, Mukherjee A, et al. Targeted disruption of the estrogen receptor-alpha gene in female mice: characterization of ovarian responses and phenotype in the adult. Endocrinology, 1999, 140: 2733–2744.
30. Cheng G, Weihua Z, Makinen S, et al. A role for the androgen receptor in follicular atresia of estrogen receptor beta knockout mouse ovary. Biol Reprod, 2002, 66: 77–84.
31. Cheng J, Lee EJ, Madison LD, et al. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett, 2004, 566(1-3): 169-172.
32. Temple JL, Scordalakes EM, Bodo C, et al.Lack of functional estrogen receptor beta gene disrupts pubertal male sexual behavior. Horm Behav, 2003, 44(5): 427-434.
33. Delbes G, Levacher C, Pairault C, et al. Estrogen receptor beta-mediated inhibition of male germ cell line development in mice by endogenous estrogens during perinatal life. Endocrinology, 2004, 145(7): 3395-3403.
34. Couse JF, Hewitt SC, Bunch DO, et al. postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta. Science, 1999, 286(5448): 2328-2331.
35. Couse JF, Yates MM, Walker VR, et al. Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) Null mice reveals hypergonadism and endocrine sex reversal in females lacking ERalpha but not ERbeta. Mol Endocrinol, 2003, 17(6): 1039-1053.
36. Horvath LG, Henshall SM, Lee CS, et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res, 2001, 61: 5331–5335.
37. Roger P, Sahla ME, Makela S, et al. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res, 2001, 61: 2537–2541.
38. Hartinan J,Lindberg K,Morani A,InZunZa J,Strom A,Gustafsson JA. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res,2006,66:11207-11213
39. Stabile LP, Davis ALG, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor a and b and show biological responses to estrogen. Cancer Res, 2002, 62: 2141–2150.
40. Foley EF, Jazaeri AA, Shupnik MA, et al. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res, 2000, 60: 245–248.
41.李建文,陶凯雄,蔡开琳. ERβ和VEGF在大肠癌中的表达及临床意义.世界华人消化杂志2007,15(24):2652-2656
42. Chu S, Mamers P, Burger HG, et al. Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors. J Clin Endocrinol Metab, 2000, 85: 1200–1205.
43. Rutherford T, Brown WD, Sapi E,et al. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol, 2000, 96: 417–421.
44. Bardin A, Hoffmann P, Boulle N, et al. Involvement of estrogen receptor beta inovarian carcinogenesis. Cancer Res, 2004, 64(16): 5861-5869.
45. Li AJ, Baldwin RL, Karlan BY. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am JObstet Gynecol, 2003, 189: 22–27.
46. Lindgren PR, Cajander S, Backstrom T, et al. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol, 2004, 221:97–104.
47. Skliris GP, Munot K, Bell SM, et al. Reduced expression of oestrogen receptor-beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol, 2003, 201: 213–220.
48. Sasaki M, Tanaka Y, Perinchery G, et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst, 2002, 94: 384–390.
49.姚青,何晓松,张建民.前列腺癌中E-钙粘素、p16及雌激素受体基因甲基化的检测及其临床意义[J].中华男科学, 2007, 12(1): 28-31.
50. Li LC, Yeh CC, Nojima D, et al. Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun, 2000, 275: 682–689.
51. Bandera CA, Takahashi H, Behbakht K,et al.Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma. Cancer Res, 1997, 57: 513–515.
52. Cheng J, Lee EJ, Madison LD, et al. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. Fed Eur Biochem Soc Lett, 2004, 566: 169–172.
53. Licznar A, Caporali S, Lucas A, et al. Identification of genes involved in growth inhibition of breast cancer cells transduced with estrogen receptor.Fed Eu. Biochem Soc Lett, 2003, 553: 445–450.
54. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, et al. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene, 2003, 22: 5011–5020.
55. Paruthiyil S, Parmar H, Kerekatte V, et al. Estrogen receptor beta inhibits human breastcancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res, 2004, 64: 423–428.
56. Strom A, Hartman J, Foster JS, et al. Estrogen receptor b inhibits 17b- estradiolstimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA, 2004.
57. Sapi E, Brown WD, Aschkenazi S, et al. Regulation of Fas ligand expression by estrogen in normal ovary. J Soc Gynecol Investig, 2002, 9: 243–250.
58. Meng-Sen L,i Qiu-LingMa, Qian Chen, et al Alpha-fetoprotein triggers hematoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells[J].World Journal of Gastroen tectology, 2005, 11(17): 2564-2569.